ABT
ABBOTT LABORATORIES
NYSE · Healthcare · Medical - Devices · US
$104.06
−0.79%Aug 11, 2026, 13:02 UTC
Abbott announced a partnership with Google to conduct a large-scale metabolic health research study.
Jul 27, 2026, 12:00 UTC
The FDA approved Freenome's SimpleScreen CRC blood-based screening test, and Abbott will commercialize it in the U.S.
Source:Jul 24, 2026, 19:58 UTC
A patient filed a class action lawsuit against Abbott Laboratories and Exact Sciences in Illinois federal court, alleging failure to safeguard sensitive personal and health information in a data theft hack claimed by ShinyHunters.
Source:Jul 16, 2026, 12:35 UTC
Abbott's cancer diagnostics business suffered a cybersecurity incident; the incident did not affect operations or product supply.
Jul 16, 2026, 00:00 UTC
Abbott Laboratories reported its Q2 2026 financial results, with revenue of $12.593 billion and GAAP diluted EPS of $0.53, and updated its full-year 2026 adjusted diluted EPS guidance to a range of $5.45 to $5.60.
Jun 29, 2026, 01:17 UTC
The U.S. Department of Justice closed a criminal probe into Abbott Laboratories over its management of a baby formula plant and opted for civil penalties instead.
Source:Jun 24, 2026, 11:36 UTC
ALZpath signed a global licensing agreement with Abbott Laboratories to develop a blood-based test for Alzheimer's disease.
Source:Jun 12, 2026, 18:29 UTC
Abbott's board of directors declared a quarterly common dividend of 63 cents per share.
Source:Jun 5, 2026, 17:57 UTC
A U.S. federal judge ruled that consumers could reasonably interpret Abbott's marketing of PediaSure as promising height growth, allowing a lawsuit to proceed.
Source:
← PreviousPage 2